BioXcel Therapeutics Financials - Benzinga

BioXcel Therapeutics Inc

BTAINASDAQ

Trade with Public

Trade with Public

$0.8038

0.00530.66%

At close: Aug 21, 5:00 PM EST

$0.8089

0.00510.63%

After Hours: Aug 21, 7:46 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Stock Report

BioXcel Therapeutics Financials

BioXcel Therapeutics (BTAI) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Earnings Scheduled For May 15, 2026

Benzinga Insights

PRO
BioXcel Therapeutics Q1 EPS $(0.54) Beats $(0.59) Estimate, Sales $206.000K Miss $349.250K Estimate

Benzinga Newsdesk

Earnings Scheduled For March 27, 2026

Benzinga Insights

PRO
BioXcel Therapeutics Q4 EPS $(0.58) Beats $(0.69) Estimate, Sales $256.000K Beat $250.000K Estimate

BioXcel Therapeutics (NASDAQ:BTAI) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.69) by 16.31 percent. This is a 83.75 percent increase over losses of $(3.57) per share

Benzinga Newsdesk

PRO
BioXcel Therapeutics Q3 EPS $(2.18) Misses $(1.13) Estimate, Sales $98.000K Miss $212.500K Estimate

BioXcel Therapeutics (NASDAQ:BTAI) reported quarterly losses of $(2.18) per share which missed the analyst consensus estimate of $(1.13) by 93.43 percent. This is a 57.67 percent increase over losses of $(5.15) per share

Benzinga Newsdesk

PRO
BioXcel Therapeutics Q2 EPS $(2.45) Beats $(3.28) Estimate, Sales $120.00K Miss $283.33K Estimate

BioXcel Therapeutics (NASDAQ:BTAI) reported quarterly losses of $(2.45) per share which beat the analyst consensus estimate of $(3.28) by 25.24 percent. This is a 27.08 percent increase over losses of $(3.36) per share

Benzinga Newsdesk